Rapamycin induces transactivation of the EGFR and increases cell survival
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Link
http://www.nature.com/articles/onc2008490.pdf
Reference61 articles.
1. Abraham RT . (1998). Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 10: 330–336.
2. Arteaga CL, Ramsey TT, Shawver LK, Guyer CA . (1997). Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J Biol Chem 272: 23247–23254.
3. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T et al. (2002). Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8: 35–40.
4. Azzariti A, Porcelli L, Gatti G, Nicolin A, Paradiso A . (2008). Synergic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors on pancreatic cancer cells. Biochem Pharmacol 75: 1035–1044.
5. Banko JL, Hou L, Poulin F, Sonenberg N, Klann E . (2006). Regulation of eukaryotic initiation factor 4E by converging signaling pathways during metabotropic glutamate receptor-dependent long-term depression. J Neurosci 26: 2167–2173.
Cited by 44 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The role of EGFR in vascular AT1R signaling: From cellular mechanisms to systemic relevance;Biochemical Pharmacology;2023-11
2. Targeting Breast Cancer: An Overlook on Current Strategies;International Journal of Molecular Sciences;2023-02-11
3. Systemic Efficacy of Sirolimus via the ERBB Signaling Pathway in Breast Cancer;Processes;2022-03-11
4. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study;European Journal of Cancer;2021-07
5. A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors;Cancer Chemotherapy and Pharmacology;2020-11-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3